GU Cancers 2024 | ASCO GU 2024: immunotherapy highlights in kidney cancer

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT, discusses his highlights presented at the ASCO GU Cancers Symposium 2024 in the field of kidney cancer, including overall survival data from trials assessing pembrolizumab and nivolumab, as well as outcomes in patients receiving belzutifan. Dr Braun additionally comments on the optimal administration route of nivolumab. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.